Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to res... Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population. Show more
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) PR Newswire GAITHERSBURG, Md., Nov. 15, 2024 GAITHERSBURG, Md., Nov. 15, 2024 /PRNewswire/ -- Novavax, Inc...
Novavax to Participate in Jefferies London Healthcare Conference PR Newswire GAITHERSBURG, Md., Nov. 13, 2024 GAITHERSBURG, Md., Nov. 13, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a...
Novavax Reports Third Quarter 2024 Financial Results and Operational Highlights PR Newswire GAITHERSBURG, Md., Nov. 12, 2024 U.S. FDA removes clinical hold on Investigational New Drug application...
U.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial PR Newswire GAITHERSBURG, Md., Nov. 11, 2024 GAITHERSBURG, Md., Nov. 11, 2024...
Novavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024 PR Newswire GAITHERSBURG, Md., Nov. 4, 2024 GAITHERSBURG, Md., Nov...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.485 | -5.25460455038 | 9.23 | 9.28 | 8.5 | 2986731 | 8.71126759 | CS |
4 | -0.255 | -2.83333333333 | 9 | 10.39 | 6.81 | 5614909 | 8.37389797 | CS |
12 | -4.005 | -31.4117647059 | 12.75 | 15.22 | 6.81 | 6232438 | 10.87859065 | CS |
26 | -6.255 | -41.7 | 15 | 23.8599 | 6.81 | 7932033 | 13.48728316 | CS |
52 | 3.225 | 58.4239130435 | 5.52 | 23.8599 | 3.5324 | 9460103 | 10.30240135 | CS |
156 | -160.255 | -94.825443787 | 169 | 236.5 | 3.5324 | 7524187 | 23.58103101 | CS |
260 | 3.625 | 70.80078125 | 5.12 | 331.5388 | 3.5324 | 6808253 | 53.86838467 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales